Dr. Goel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Yawkey 12, Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-335-3937
Education & Training
The University of Adelaide Faculty of Health SciencesClass of 1996
Certifications & Licensure
MA State Medical License 2018 - 2024
Clinical Trials
- Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Start of enrollment: 2017 May 26
Publications & Presentations
PubMed
- 928 citationsCDK4/6 inhibition triggers anti-tumour immunityShom Goel, Molly J. DeCristo, April C. Watt, Haley BrinJones, Jaclyn Sceneay
Nature. 2017-08-24 - 298 citationsOvercoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 InhibitorsShom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon
Cancer Cell. 2016-03-14 - 172 citationsTargeting CDK4 and CDK6 in cancer.Shom Goel, Johann S Bergholz, Jean J Zhao
Nature Reviews. Cancer. 2022-06-01
Press Mentions
Breast Cancer Updates from ESMO 2022September 21st, 2022
Studies Highlight ‘Potential New Targets for Immunotherapy’August 22nd, 2017
Drug Combination Drives HER2-Positive Breast Cancer Brain Metastases into Long-Term Remission in Mouse StudyJune 6th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
